Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 12/20 | 0.48 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 3/20 | 0.45 |
| ▸ | FABP3 | P05413 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215832 | 0.83 | AKR1C3 (0.73) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL4215780 | 0.81 | IGF2BP2 (0.57) | CASP6MCL1AKR1C3AKR1C2ACLY | |
| SCHEMBL4212766 | 0.81 | AKR1C3 (0.48) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL4361087 | 0.81 | IGF2BP2 (0.56) | AKR1C3AKR1C2ACLYIGF2BP2AURKA | |
| SCHEMBL4214728 | 0.78 | ACLY (0.54) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL4221963 | 0.77 | DHODH (0.49) | AKR1C3AKR1C2ACLYFABP4FABP5 | |
| SCHEMBL4217337 | 0.76 | FABP3 (0.73) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL4218109 | 0.76 | ACMSD (0.60) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL4223433 | 0.75 | FABP4 (0.58) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL4216661 | 0.75 | FTO (0.58) | AKR1C3ACLYFABP4FABP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | KDM4E 3540/4885APAF1 1577/4885RECQL 2297/4885 |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | KDM4E 2222/4885APAF1 701/4885RECQL 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.